Galantamine, an acetylcholinesterase (AChE) inhibitor used for symptomatic treatment of Alzheimer's disease (AD), shows substantial inter-individual variability in clinical response. This evidence concerns the gene ACHE and early-onset autosomal dominant Alzheimer disease.